NetraMark Holdings Inc. announces the addition of Abhishek Agrawal to the NetraMark Advisory Board. Mr. Agrawal comes to NetraMark with over two decades of experience in leading strategy, transformation and product development in the Healthcare industry. He has held leadership roles at GSK and Novartis launching over five new molecular entities (NMEs) and is an active advisor with the Alzheimer's Drug Discovery Foundation (ADDF), Gates Ventures and Zoic Capital.

Mr. Agrawal, also brings a deep management consulting base from IQVIA, Strategic Decisions Group (SDG) and Bionest Partners; where he led several large R&D and commercial portfolio optimization projects for Pfizer, Johnson &Johnson, Biogen and Genentech. He has worked across the globe including North America, Japan, China and Central America. The addition of Mr. Agrawal is important as the Company continues to make strides in support of its commercialization efforts for its NetraMark AI based clinical development offerings.

The inclusion of key pharmaceutical industry leaders on the Advisory Board puts NetraMark in a better position to ensure its solutions address client needs. His interests and understanding of NetraMark have been cultivated over the last four years observing the philosophy and evolution of the technology and therefore his understanding of the right commercialization plan for the Company can be leveraged immediately.